logo
Coffee May Hide Secret to Diabetes Management

Coffee May Hide Secret to Diabetes Management

Newsweek5 hours ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Compounds found in coffee beans could offer a new way to help people living with diabetes manage their condition.
Three compounds in particular have demonstrated significant inhibitory effects on α-glucosidase, a key enzyme in carbohydrate digestion.
This could lead to new functional food ingredients targeting type 2 diabetes, according to the study by the Kunming Institute of Botany in China.
Around 1 in 10 Americans (more than 38 million people) live with diabetes, of which 90–95 percent have type 2. This occurs when insulin doesn't work properly or there's not enough of it.
Current management methods include checking blood sugar (or glucose) levels and keeping them close to a personal target level to prevent or delay complications.
Healthy eating, being active and getting enough sleep may be enough to help manage the condition in some circumstances, or doctors may prescribe metformin, insulin or other medicines (along with lifestyle factors).
Coffee beans in the hand's of a worker.
Coffee beans in the hand's of a worker.
Schwede-Photodesign/Getty Images
Building on this, the new study shows promising anti-diabetic potential and helps to expand our understanding of coffee's functional components, according to the researchers.
Functional foods are known for both their nutritional value and for delivering "biologically active" compounds with potential health benefits, like antioxidant, neuroprotective, or glucose-lowering properties.
"Coffee diterpenes are a class of characteristic components in coffee, which have potential biological activities including the prevention of cancer, obesity, diabetes, and other diseases," the researchers wrote in their paper.
"Due to the complex chemical composition of roasted coffee beans, analyzing the composition and potential activity of coffee diterpenes has always been a challenge."
To solve this, scientists have been trying more advanced techniques called nuclear magnetic resonance (NMR) and liquid chromatography–mass spectrometry (LC-MS/MS) to speed up the discovery of the bioactive molecules, as found in "chemically diverse" systems like roasted coffee.
"Functional food ingredients could potentially help with managing glucose, in principle. But for an ingredient to be useful, we need to know the effective dose, safety, and bioavailability in humans," Signe Svanfeldt, lead nutritionist at Lifesum, told Newsweek.
"Many promising lab results never translate into practical benefits. So, while functional ingredients may support glucose management, they are always adjuncts to diet, activity, and medication—not replacements."
In this study, the team developed a three-step, activity-oriented strategy to efficiently identify bioactive diterpene esters in roasted coffee arabica beans. Arabica is the most popular of four main types of coffee beans, alongside Robusta, Liberica and Excelsa.
"The study isolated specific molecules from coffee beans, not brewed coffee itself. Normal coffee consumption has previously been linked in large population studies to a lower risk of developing type 2 diabetes and better survival in people with diabetes. Both regular and decaf coffee show this, suggesting compounds beyond caffeine are beneficial," said Svanfeldt.
The scientists' goal was to discover both abundant and trace-level compounds with α-glucosidase inhibitory activity, while minimizing the use of solvents and analysis time.
"The structures of the three new compounds were determined through comprehensive spectral analysis," the researchers wrote.
The new isolated diterpene esters were named caffaldehydes A, B, and C. In the study, these compounds, differing in their fatty acid chains, showed a moderate α-glucosidase inhibitory activity with values more potent than the control drug acarbose.
Acarbose is sometimes used to help people with type 2 diabetes when changes to diet, or other medications have been unable to bring down blood sugar levels to their target range. It slows down the digestion of starchy foods like potatoes, pasta and rice from the gut, meaning blood sugar levels rise more slowly after meals.
"To explore trace active diterpene esters of the same type in coffee, a molecular network based on LC-MS/MS was constructed, and three novel coffee diterpene esters were identified," the authors added.
These three additional unknown compounds were closely related to caffaldehydes A–C, sharing "common fragment ions but featuring different fatty acids".
Their absence in compound databases confirmed their novelty.
The findings demonstrate the effectiveness of this approach in discovering structurally diverse, biologically relevant compounds in complex food matrices (structures and interactions) like roasted coffee, according to the study.
It could also pave the way to developing new functional food ingredients or nutraceuticals derived from coffee, targeting glucose regulation and potentially aiding in diabetes management.
Happy mature woman checking blood sugar level at home with monitor.
Happy mature woman checking blood sugar level at home with monitor.
stefanamer/Getty Images
"The new compounds in this paper are not proven to have effects in humans yet. Drinking coffee is fine as part of a healthy lifestyle, but it shouldn't be seen as a treatment for diabetes," said Svanfeldt.
The researchers also said the strategy used in their study could be adapted for rapid screening of bioactive metabolites in other complex food matrices.
Next steps will include exploring the biological activity of the newly identified trace diterpenes and assessing their safety and efficacy in vivo.
While Svanfeldt said, if developed further, these findings would most likely lead to an "add-on to standard care", she emphasized: "Coffee, or these compounds, cannot replace CGMs, glucose testing, medications, or lifestyle measures.
"Caffeine tolerance is highly individual. While up to 400mg of caffeine per day—about three to four cups of brewed coffee, is generally considered safe for most healthy adults, some may experience side effects such as anxiety, sleep disturbances, or gastrointestinal discomfort at lower levels."
Newsweek has reached out to the researchers for additional comment.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question type 2 diabetes? Let us know via health@newsweek.com.
Reference
Hu, G., Quan, C., Al-Romaima, A., Dai, H., Qiu, M., Hu, G., Quan, C., Al-Romaima, A., Dai, H., & Qiu, M. (2024). Bioactive oriented discovery of diterpenoids in Coffea arabica basing on 1D NMR and LC-MS/MS molecular network. Beverage Plant Research, 5(1). https://doi.org/10.48130/bpr-0024-0035
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medicaid Implementing Major Change
Medicaid Implementing Major Change

Newsweek

time7 minutes ago

  • Newsweek

Medicaid Implementing Major Change

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Trump administration's Centers for Medicare & Medicaid Services (CMS) has rolled out a new initiative requiring states to conduct monthly checks on Medicaid and CHIP (Children's Health Insurance Program) enrollees, according to a new report by Fox News' Alec Schemmel. The change would affect those whose citizenship or immigration status cannot be confirmed through federal databases like the Social Security Administration and DHS's SAVE program. According to CMS, the first round of individual reports went out Tuesday to all 50 states and D.C., with states expected to verify status and report back. "We are tightening oversight of enrollment to safeguard taxpayer dollars and guarantee that these vital programs serve only those who are truly eligible under the law," HHS Secretary Robert F. Kennedy Jr. told Fox News. CMS Administrator Dr. Mehmet Oz added that "every dollar misspent is a dollar taken away from an eligible, vulnerable individual in need." This is a breaking news story. Updates to follow.

‘Kitten Lady' Hannah Shaw Teams with Hill's Pet Nutrition to Discuss Clear The Shelters 2025 with YourUpdateTV
‘Kitten Lady' Hannah Shaw Teams with Hill's Pet Nutrition to Discuss Clear The Shelters 2025 with YourUpdateTV

Associated Press

time29 minutes ago

  • Associated Press

‘Kitten Lady' Hannah Shaw Teams with Hill's Pet Nutrition to Discuss Clear The Shelters 2025 with YourUpdateTV

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Shelters across the country continue to face capacity challenges, slowed adoptions and stretched resources, with 5.8 million cats and dogs entering shelters last year alone, according to Shelter Animals Count. Now in its 11th year, NBCUniversal Local's Clear The Shelters campaign returns alongside Hill's Pet Nutrition (Hill's), the campaign's longest-running national sponsor, to help address the crisis and encourage shelter adoptions. Recently, Award-Winning Kitten Rescuer and Best-Selling Author, Kitten Lady Hannah Shaw, teamed with Hill's for a nationwide media tour to share helpful tips for prospective pet parents, from preparing your home to getting a healthy start with high-quality nutrition. She talked about what adopters can expect during the adjustment period, including how to build trust, encourage healthy routines and integrate a new pet into the family. Shaw also spoke to the unspoken feeling that in order to adopt, one has to be the 'perfect pet parent.' According to Hill's 2025 State of Shelter Pet Adoption Report, younger Americans often feel a pressure to meet a 'gold standard' of pet care, leading to hesitation and guilt about adoption. Shaw reassured that committed care, even if imperfect, is truly enough and that much of pet parenthood is learned through experience. Since 2015, Clear The Shelters has helped nearly 1.2 million pets find loving homes and raised more than $5 million for participating shelters across the country. After setting a single-year adoption record in 2024, this year's goal is bigger than ever: make 2025 another record-breaking year and give even more pets a second chance. During Clear The Shelters, Hill's continues its 23-year commitment to shelter pets and animal welfare professionals through its Hill's Food, Shelter & Love program. The program has supported more than 15 million adoptions and donated more than $300 million in science-led nutrition to more than 1,000 North American shelters. There are many ways to get involved with Clear The Shelters: Visit to find more information about Clear The Shelters 2025 and resources about Hill's Pet Nutrition and its support of shelter pets. About Hannah Shaw Hannah Shaw is an award-winning kitten rescuer, humane educator and New York Times bestselling author dedicated to protecting vulnerable felines. Known as Kitten Lady, she creates educational content used by shelters and foster parents worldwide, with over 4 million followers across social platforms. Shaw is the founder of the nonprofit Orphan Kitten Club and author of Tiny But Mighty and Cats of the World. She lives in California with her husband, fellow animal advocate Andrew Marttila, and a rotating cast of foster kittens. * YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of Hill's Pet Nutrition Dante Muccigrosso Director of Media Integration & Client Reporting E: [email protected] C: 973.524.0104 A video accompanying this release is available at

Cencora directors agree to $111M settlement over alleged opioid mismanagement
Cencora directors agree to $111M settlement over alleged opioid mismanagement

Yahoo

time39 minutes ago

  • Yahoo

Cencora directors agree to $111M settlement over alleged opioid mismanagement

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Cencora directors have agreed to pay upwards of $111 million to settle allegations that they failed to stop the drug distributor from perpetuating the U.S. opioid epidemic. The lawsuit brought by pension funds accused Cencora's leadership of ignoring red flags around how the company was dispensing the highly addictive painkillers for years — including dubiously large opioid shipments — and failing to properly monitor opioid sales. The settlement disclosed Friday in a filing with the Delaware Chauncery Court is Cencora's latest financial penalty over its role in the opioid crisis. Still, it amounts to a slap on the wrist compared to the billions of dollars that Cencora has already agreed to pay to settle opioid-related litigation brought by state and local governments. Dive Insight: In 2021, Lebanon County Employees' Retirement Fund and a health plan maintained by the Teamsters union sued Cencora's directors for breaching their duty to stockholders by failing to stop Cencora from improperly distributing opioids. Over 1 million Americans have died of overdoses related to opioids since 1999, but deaths spiked in between 2017 and 2023 as the potent painkillers became more readily available and easily misused, according to the Centers for Disease Control and Prevention. During the epidemic, Cencora failed to 'adopt, implement, or oversee reasonable policies and practices to prevent the unlawful distribution of opioids and failed to act when presented with evidence of widespread illegal opioid sales,' the pension funds argued in the Delaware suit. In 2022, a Delaware judge dismissed the case based on a decision from a West Virginia court in Cencora's favor in separate litigation, saying in a ruling it 'knock[ed] the stuffing out of the plaintiffs' claim[s].' However, the Delaware Supreme Court revived the case in 2023 after the plaintiffs appealed. Following mediation in June, both Cencora and the pension funds accepted an arbitor's proposal that Cencora pay $111.3 million to settle the case, according to court documents. The amount was solidified in the formal settlement disclosed on Friday. 'Plaintiffs and Plaintiffs' Counsel have determined that the Settlement is fair, reasonable, adequate, and in the best interests of the Company and its stockholders,' the settlement reads. Meanwhile, 'Defendants have denied, and continue to expressly deny, each and all of the claims and contentions alleged by Plaintiffs ... Defendants are entering into this Stipulation and the Settlement solely to eliminate the burden, expense, disruption, and distraction inherent in further litigation.' When contacted for comment, a Cencora spokesperson stressed that the settlement is to avoid further litigation and contains no admission of liability or wrongdoing. The company, which rebranded from AmerisourceBergen in 2023, is already on the hook for billions of dollars over its alleged role in the opioid epidemic. The company agreed in 2022 to pay $6.4 billion over 18 years as part of a nationwide settlement resolving the lion's share of lawsuits filed against drug distributors by state and local governments. Scattershot lawsuits, such as this from the pension funds, have continued, resulting in smaller settlements. For example, last fall Cencora and two other major drug distributors agreed to pay $300 million to settle opioid-related litigation from a number of health insurers and benefits plans. Thousands of lawsuits have taken distributors, drugmakers, pharmacies and doctors to task for their role in flooding the country with opioids. Litigation has resulted in roughly $50 billion in settlements to date. Recommended Reading Drug distributors agree to $300M settlement for role in opioid epidemic Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store